![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/20/2901371/0/en/Basilea-partners-oncology-drug-candidate-lisavanbulin-with-Glioblastoma-Foundation.html
https://www.globenewswire.com/news-release/2024/05/03/2874833/0/en/Basilea-reports-presentation-of-new-data-for-ceftobiprole-Zevtera-at-ESCMID-Global-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868902/0/en/Basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-annual-general-meeting.html
https://www.expresspharma.in/basileas-zevtera-will-play-unique-yet-critical-role-in-mrsab-globaldata/
https://www.basilea.com/news/news/basilea-awarded-carb-x-grant-to-develop-recently-acquired-novel-class-of-antibiotics?type=1546938654
https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses
https://www.globenewswire.com//news-release/2024/03/11/2843460/0/en/Continued-strong-Cresemba-isavuconazole-sales-performance-in-Asia-Pacific-and-China-triggers-milestone-payment-to-Basilea.html
https://www.globenewswire.com//news-release/2024/02/13/2827947/0/en/Basilea-reports-strong-2023-full-year-results-with-profitability-significantly-above-guidance-whilst-substantially-expanding-the-R-D-portfolio.html
https://www.globenewswire.com//news-release/2024/01/19/2812103/0/en/Cresemba-sales-in-Latin-America-trigger-first-sales-milestone-payment-to-Basilea.html
https://www.globenewswire.com//news-release/2024/01/15/2808936/0/en/Basilea-announces-acquisition-of-preclinical-antibiotics-program-from-Spexis.html